Stock Scorecard
Stock Summary for BioXcel Therapeutics Inc (BTAI) - $2.86 as of 3/28/2024 5:35:30 PM EST
Total Score
4 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for BTAI
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for BTAI
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for BTAI
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for BTAI
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for BTAI
Financial Details for BTAI
Company Overview |
|
---|---|
Ticker | BTAI |
Company Name | BioXcel Therapeutics Inc |
Country | USA |
Description | BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/6/2024 |
Stock Price History |
|
Last Day Price | 2.86 |
Last Day Price Updated | 3/28/2024 5:35:30 PM EST |
Last Day Volume | 531,733 |
Average Daily Volume | 1,071,809 |
52-Week High | 29.56 |
52-Week Low | 1.91 |
Last Price to 52 Week Low | 49.74% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 100.07 |
Sector PE | 60.76 |
5-Year Average PE | -5.70 |
Free Cash Flow Ratio | 1.34 |
Industry Free Cash Flow Ratio | 12.70 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 2.65 |
Total Cash Per Share | 2.13 |
Book Value Per Share Most Recent Quarter | -1.89 |
Price to Book Ratio | 3.97 |
Industry Price to Book Ratio | 5.57 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 63.37 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 30,576,700 |
Market Capitalization | 87,449,362 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -8.02% |
Reported EPS 12 Trailing Months | -6.15 |
Reported EPS Past Year | -6.15 |
Reported EPS Prior Year | -5.91 |
Net Income Twelve Trailing Months | -179,053,000 |
Net Income Past Year | -179,053,000 |
Net Income Prior Year | -165,757,000 |
Quarterly Revenue Growth YOY | 58.00% |
5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 65,221,000 |
Total Cash Past Year | 65,221,000 |
Total Cash Prior Year | 193,725,000 |
Net Cash Position Most Recent Quarter | -138,057,000 |
Net Cash Position Past Year | -138,057,000 |
Long Term Debt Past Year | 203,278,000 |
Long Term Debt Prior Year | 194,488,000 |
Total Debt Most Recent Quarter | 203,278,000 |
Equity to Debt Ratio Past Year | -0.39 |
Equity to Debt Ratio Most Recent Quarter | -0.39 |
Total Stockholder Equity Past Year | -56,508,000 |
Total Stockholder Equity Prior Year | 76,775,000 |
Total Stockholder Equity Most Recent Quarter | -56,508,000 |
Options |
|
Put/Call Ratio | 1.07 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.11 |
MACD Signal | -0.08 |
20-Day Bollinger Lower Band | 2.15 |
20-Day Bollinger Middle Band | 3.10 |
20-Day Bollinger Upper Band | 4.06 |
Beta | 0.42 |
RSI | 39.79 |
50-Day SMA | 7.97 |
200-Day SMA | 24.48 |
System |
|
Modified | 3/27/2024 8:05:32 PM EST |